Ocular Therapeutix (OCUL) Receivables - Other (2013 - 2017)
Ocular Therapeutix's (OCUL) quarterly Receivables - Other came in at $688000.0 in Q1 2017, up 68700.0% quarter-over-quarter from $1000.0 in Q3 2014.
Ocular Therapeutix (OCUL) Receivables - Other (2013 - 2017) Analysis & Trends
Ocular Therapeutix's Receivables - Other history runs 3 years deep, the most recent figure standing at $688000.0 for Q1 2017.
- On a quarterly basis, Receivables - Other changed N/A year-over-year to $688000.0 in Q1 2017; TTM through Mar 2017 was $688000.0, a N/A change from a year earlier, with the FY2013 full-year figure at $19000.0, changed N/A from the prior year.
- Receivables - Other advanced to $688000.0 in Q1 2017 per OCUL's latest filing, from $1000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $688000.0 in Q1 2017 and bottomed at $1000.0 in Q2 2014.
- The 3-year median for Receivables - Other is $10000.0 (2013), against an average of $177250.0.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ocular Therapeutix | 1.93 Bn | 1.93 Bn | 9.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | 688,000.00 |
| Mar 31, 2017 | 688,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 1,000.00 |
| Dec 31, 2013 | 19,000.00 |
| Dec 31, 2013 | 19,000.00 |